EQS-News: Pentixapharm Holding AG
/ Key word(s): Personnel
Berlin, Germany, March 3, 2025 - Several previously announced personnel changes in the governing bodies of the Pentixapharm Group have taken effect as of March 1, 2025. The Management Board of the parent company Pentixapharm Holding AG is now identical in composition to the Management Board of the wholly owned operational subsidiary Pentixapharm AG. Both companies are now led by Dr. Dirk Pleimes and Henner Kollenberg. Dr. Andreas Eckert, who was temporarily appointed as sole member of the Management Board of the holding company in November 2024 under § 105(2) of the German Stock Corporation Act following the health-related departure of Pentixapharm founder Dr. Hakim Bouterfa, has returned to the Supervisory Board of Pentixapharm Holding AG. He was re-elected as Chairman there. With his return to the Supervisory Board, Dr. Harald Hasselmann's Supervisory Board mandate in Pentixapharm Holding AG has also been reactivated. Hasselmann had suspended his mandate since October due to potential conflicts of interest. Frank Perschmann, who had been acting as Chairman of the Supervisory Board of Pentixapharm Holding AG in recent months, left the board as planned with Eckert's return.
About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds and early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.
Pentixapharm Holding AG
03.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Pentixapharm Holding AG |
Robert-Rössle-Straße 10 | |
13125 Berlin | |
Germany | |
E-mail: | info@pentixapharm.com |
Internet: | https://www.pentixapharm.com/ |
ISIN: | DE000A40AEG0 |
WKN: | A40AEG |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2094397 |
End of News | EQS News Service |
|
2094397 03.03.2025 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.